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Background: As well known, angina pectoris is caused by myocardial ischemia due to an imbalance between myocardial perfusion and 
oxygen demand. Despite treatment with standard therapy (ST) plus cardiac revascularization, many patients remain symptomatic. It is 
necessary to introduce new strategies to reduce angina episodes. The aim was to evaluate the effects of Ivabradine and Ranolazine 
plus ST vs only ST in term of exercise tolerability and incidence of angina episodes at 30 days. The secondary aim was to evaluate the 
incidence of weekly angina episodes and re-hospitalization at 6 and 12 months.
methods: 135 consecutive patients who underwent percutaneous coronary intervention plus stent implantation were enrolled. Patients 
were randomized in three arms to receive: Ivabradine, Ranolazine or ST alone. After 30 days, all patients were submitted to exercise 
treadmill test (ETT); symptoms, EKG variations and maximal time exercise were recorded. Clinical follow-up was performed at 1, 6 and 12 
months.
results: Patients were randomized in Ivabradine Group (IG), 45 subjects, Ranolazine Group (RG), 45 subjects, Control Group (CG), 45 
subjects. No baseline differences were found among the groups. All patients performed ETT and only 11.1% of IG and RG did not reach 
the threshold of 6 minutes vs 28.8% of GC (p=0.03). In IG and in RG 5 patients developed angina in the first 6 minutes of exercise (CG vs 
IG vs RG p=0.03). At 30 days, 24.4% developed weekly angina during daily moderate exercises in CG vs 4.5% in IG (p=0.007) and 8.8% 
in RG (p=0.04). At 6 months follow-up, significative differences in angina onset were found between RG (5 patients) vs IG (7 patients) vs 
CG (19 patients) (CG vs IG p= 0.005; CG vs RG p=0.008). At 1 year, weekly angina was greater in CG (42.2%) compared with both RG 
(p=0.002) and IG (p=0.005). At 1 year, re-hospitalization for angina worsening was necessary in 2 patients in IG vs 9 patients in CG and 5 
patients in RG (CG vs IG p=0.02).
Conclusion:  The addition of either Ivabradine or Ranolazine to the ST in patients with complete cardiac revascularization produced a 
significant improvement of exercise tolerability, a decrease of daily angina episodes as well as of re-hospitalization for angina worsening.
